Validation of proteomic‐based discovery with tissue microarrays

Proteomics is routinely utilized for biomarker discovery above and beyond its general use in basic science. Multiple platforms provide a robust pipeline of candidates that require verification and validation as biomarkers of disease. Within the field of oncology, tissue biomarkers are in high demand as tools of diagnosis, prognosis and prediction of response to therapy. By examining the proteome, rather than the transcriptome, there is the potential to directly interrogate the drug targets and define biomarkers at the most proximate level. Toward these ends, the tissue microarray has become a common platform for verification of results and validation of clinically relevant biomarkers. Immunohistochemistry remains the most common analytical method applied to TMA and provides a direct channel toward clinical application. The TMA stands at the crossroads of proteomics and pathology, combining formalin‐fixed paraffin‐embedded tissue as an analyte and IHC as a method of assay.

[1]  S. Steinberg,et al.  Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. , 2007, Oncology reports.

[2]  Quan-hong Wang,et al.  A Multiplex Tissue Immunoblotting Assay for Proteomic Profiling: A Pilot Study of the Normal to Tumor Transition of Esophageal Squamous Cell Carcinoma , 2006, Cancer Epidemiology Biomarkers & Prevention.

[3]  Joe M. Byrne,et al.  Raman Spectroscopic Evaluation of Efficacy of Current Paraffin Wax Section Dewaxing Agents , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[4]  S. Hewitt.  Design, construction, and use of tissue microarrays. , 2004, Methods in molecular biology.

[5]  D. Slamon,et al.  Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins. , 2001, The American journal of pathology.

[6]  Emanuel F Petricoin,et al.  Signal pathway profiling of ovarian cancer from human tissue specimens using reverse‐phase protein microarrays , 2003, Proteomics.

[7]  Stephen M Hewitt,et al.  The application of tissue microarrays in the validation of microarray results. , 2006, Methods in enzymology.

[8]  L. Montanaro,et al.  Evaluation of Thymidylate Synthase Protein Expression by Western Blotting and Immunohistochemistry on Human Colon Carcinoma Xenografts in Nude Mice , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  S. Hewitt,et al.  Transfer and multiplex immunoblotting of a paraffin embedded tissue , 2006, Proteomics.

[10]  W. Travis,et al.  Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[12]  S. Hewitt,et al.  Infrared spectroscopic imaging for histopathologic recognition , 2005, Nature Biotechnology.

[13]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[14]  F. Pontén,et al.  Antibody-based Proteomics for Human Tissue Profiling , 2005, Molecular & Cellular Proteomics.

[15]  Clive R Taylor,et al.  Recommendations for Improved Standardization of Immunohistochemistry , 2007, Applied immunohistochemistry & molecular morphology : AIMM.

[16]  I. Mazo,et al.  Expression of EIF3-p48/INT6, TID1 and Patched in cancer, a profiling of multiple tumor types and correlation of expression. , 2007, Journal of biomedical science.

[17]  S. Bilke,et al.  Proteomic expression profiling of thyroid neoplasms , 2007, Proteomics. Clinical applications.

[18]  Stephen M Hewitt,et al.  Discovery of protein biomarkers for renal diseases. , 2004, Journal of the American Society of Nephrology : JASN.

[19]  Peter Houghton,et al.  Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis. , 2007, Cancer research.

[20]  S. Hewitt,et al.  Tissue microarrays as a platform for proteomic investigation , 2007, Journal of Molecular Histology.

[21]  D. Murphy,et al.  Interlaboratory comparison of immunohistochemical testing for HER2: results of the 2004 and 2005 College of American Pathologists HER2 Immunohistochemistry Tissue Microarray Survey. , 2009, Archives of pathology & laboratory medicine.

[22]  Gallya Gannot,et al.  Layered expression scanning: multiplex molecular analysis of diverse life science platforms. , 2007, Clinica chimica acta; international journal of clinical chemistry.

[23]  D. Wong,et al.  Dissecting the Akt/Mammalian Target of Rapamycin Signaling Network: Emerging Results from the Head and Neck Cancer Tissue Array Initiative , 2007, Clinical Cancer Research.

[24]  S. Hewitt,et al.  Promises and challenges of predictive tissue biomarkers. , 2007, Biomarkers in medicine.

[25]  William C Reinhold,et al.  Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. , 2003, Cancer research.

[26]  Stephen M Hewitt,et al.  Tissue microarrays enabling high-throughput molecular pathology. , 2007, Current opinion in biotechnology.

[27]  Stephen M Hewitt,et al.  Tissue microarrays: bridging the gap between research and the clinic , 2005, Expert review of proteomics.

[28]  L. Hafer,et al.  Antibodies immunoreactive with formalin-fixed tissue antigens recognize linear protein epitopes. , 2006, American journal of clinical pathology.

[29]  M. García-Closas,et al.  Hormonal markers in breast cancer: coexpression, relationship with pathologic characteristics, and risk factor associations in a population-based study. , 2007, Cancer research.

[30]  Debashis Ghosh,et al.  alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. , 2002, JAMA.